Journal article
DOUBLE-BLIND RANDOMISED TRIAL OF ORG 10172 LOW-MOLECULAR-WEIGHT HEPARINOID IN PREVENTION OF DEEP-VEIN THROMBOSIS IN THROMBOTIC STROKE
Abstract
In a double-blind, randomised trial Org 10172 low-molecular-weight (LMW) heparinoid was compared with placebo in the prevention of deep-vein thrombosis in patients with acute thrombotic stroke. Prophylaxis was started within 7 days of the onset of stroke with a loading dose of 1000 anti-factor-Xa units intravenously followed by a fixed dose of 750 anti-factor-Xa units twice a day subcutaneously; it was continued for 14 days or until hospital …
Authors
Turpie AG; Hirsh J; Jay R; Andrew M; Hull R; Levine M; Carter C; Powers P; Magnani H; Gent M
Journal
The Lancet, Vol. 329, No. 8532, pp. 523–526
Publisher
Elsevier
Publication Date
March 1987
DOI
10.1016/s0140-6736(87)90173-5
ISSN
0140-6736
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Acute DiseaseAdultAgedAged, 80 and overCerebrovascular DisordersChondroitin SulfatesClinical Trials as TopicDermatan SulfateFemaleFibrinolytic AgentsFollow-Up StudiesGlycosaminoglycansHeparinHeparinoidsHeparitin SulfateHumansInjections, IntravenousInjections, SubcutaneousMaleMiddle AgedRadiographyRandom AllocationThrombosisTime Factors